F114. THE EVOLUTION OF LONG-ACTING ANTIPSYCHOTICS USE IN QUEBEC BETWEEN 2003 AND 2017

摘要

Long-acting injectable antipsychotics (LAIs) are recommended to decrease relapse in SZ and their relevance is acknowledged in every treatment guideline available internationally. Yet their rate of use is reported to be very low (6%) in Canada, based on a paper by Williams et al. It could be hypothesized that the fact that second generation LAIs (SGA-LAIs) had just become available might have accounted for these modest rates of use, given the strong inclination of clinicians to prefer prescribing SGAs, that had been previously available only in an oral form. However, this paper dates were published in 2006, and we are unaware from any other data on possible changes in LAI used that could have occurred following the increasing availability of new second-generation LAIs or after the publication of Québec and Canada recommendations of experts. The present report examines the changes in rates of LAIs in Québec from 2003 until 2017.